We further investigated the relationship between ptpn6 alteration and prognosis in pan-cancer, and found that tumor patients with genetic alterations in ptpn6 had worse OS (p = 8.571e-3) and DSS (p = 0.0412) than patients without alterations, but no difference in DFS (p = 0.994) and PFS (p = 0.0804) between the two groups (Fig. 7C). The gene discussed is PTPN6; the disease is neoplasm.